capsaicin (Zostrix, Qutenza)
Jump to navigation
Jump to search
Introduction
Tradename: Zostrix, Qutenza.
Indications
- temporary relief of pain due to:
* on list of medications to avoid; limited effectivness[8]
Dosage
- apply up to QID
- Qutenza must be applied to the skin by a healthcare professional
- it can be used for 60 minutes, once every 3 months[5]
Cream: 0.025%, 0.075%. 45 g
Transdermal patch Qutenza: 8%
Adverse effects
- burning of skin & mucous membranes
- stinging
- erythema
Mechanism of action
depletion of substance P
Notes
- Qutenza cost: $700/treatment (2010)
More general terms
Component of
- capsaicin/lidocaine
- camphor/capsaicin/methyl salicylate
- capsaicin/salicylate
- capsaicin/menthol/methyl salicylate
- capsaicin/lidocaine/menthol/methyl salicylate
- camphor/capsaicin/menthol/methyl salicylate/peppermint oil/zinc oxide
- camphor/capsaicin/menthol/methyl salicylate
- camphor/capsaicin/menthol
- capsaicin/turpentine
- capsaicin/menthol
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- ↑ Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
- ↑ 4.0 4.1 Journal Watch 24(11):91, 2004 Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004 Apr 24;328(7446):991. Epub 2004 Mar 19. Review. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/15033881 <Internet> http://bmj.bmjjournals.com/cgi/content/full/328/7446/991
- ↑ 5.0 5.1 FDA NEWS RELEASE, Nov. 17, 2009 FDA Approves New Drug Treatment for Long-Term Pain Relief after Shingles Attacks http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm191003.htm
Qutenza prescribing information http://www.qutenza.com/_docs/qutenza_full_PI_.pdf - ↑ 6.0 6.1 Deprecated Reference
- ↑ Prescriber's Letter 17(5): 2010 COMMENTARY: Qutenza: A High Dose Capsaicin Patch GUIDELINES: Treatment of Postherpetic Neuralgia (QSS-ANN, 2004) GUIDELINES: Prevention of Herpes Zoster (ACIP, 2008) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260521&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 8.0 8.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/